Circulating levels of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and colorectal adenomas: a meta-analysis
Lixisenatide (ADLYXIN) Phonetic pronunciation: LIX i SEN a tide / ad LIX in Mnemonic: Add licks in a Tide (Pod) Year of release: 2016 Price range: $690$710 FDA-approved for: Type 2 diabetes Mechanism: GLP-1 receptor agonist Available doses: 10 mcg, 20 mcg Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none in a bubble Lixisenatide (Adlyxin) is the newer exendin-based GLP analog
Wang S, Zhu H, Pan L, Zhang M, Wan X, Xu H, et al
1), induction of tumor cell apoptosis (Fig
(2003b)
[1] [2] Whilst highly effective, gastrointestinal side effectsparticularly nausea and vomitingare amongst the most commonly reported adverse reactions